Navigation Links
Genes Could Highlight Plavix Users at Clot Risk After Stent
Date:10/25/2011

By Amanda Gardner
HealthDay Reporter

TUESDAY, Oct. 25 (HealthDay News) -- Scientists have identified mutations in three genes that make certain patients more likely to have a potentially fatal blood clot after undergoing heart stent placement.

The genes are involved in metabolism of the drug Plavix (clopidogrel), a widely used blood thinner, and in platelet formation, according to a study published in the Oct. 26 issue of the Journal of the American Medical Association.

"This goes back to the idea of tailored medicine but [gene testing] is not feasible to do on everybody," said Dr. John Gassler, associate professor of medicine at the University of Rochester Medical Center, who was not involved with the research. "This study is very strongly thought-provoking but I don't think it can alter practice until it's been evaluated [further]."

The authors of the study also reported that a higher initial dose of Plavix reduced the risk of stent thrombosis (blood clot formation), while using proton pump inhibitors -- common drugs to treat gastroesophageal reflux disease (GERD) and stomach ulcers -- upped the risk.

People who get stents to prop open blocked arteries routinely receive two different blood thinners to reduce the risk of stent thrombosis. This has cut the rate of stent thrombosis tremendously, but up to 4 percent of patients still end up with this devastating complication, according to background information in the study.

The study authors analyzed 23 gene variants in 15 genes in 123 patients who had undergone percutaneous coronary intervention in France and who had experienced stent thrombosis.

These patients were compared to 246 similar patients who had not had stent thrombosis.

Three genotypes and two clinical factors -- Plavix loading (initial) dose and use of proton pump inhibitors -- all affected the risk of stent thrombosis.

When the investigators combined the clinical and risk factors, they found that those in the highest risk category had a sevenfold increased risk of stent thrombosis versus patients with the lowest risk profile.

"When we combine everything we have a very good predictive value, which is around 80 percent," said study co-first author, Dr. Jean-Sebastien Hulot, director of Pharmacogenomics & Personalized Therapeutics of the Cardiovascular Research Center at Mount Sinai School of Medicine in New York City.

But while the clinical variables are easy enough to assess, genetic information is not so easy to come by, at least not yet. Right now, results of genetic tests take about a week to come back.

"It would make sense to have the results in a couple of hours and some companies are developing this kind of testing," Hulot said. "In the near future we can have the results in hours. The markers aren't valuable right now but they will be in the near future."

More information

The U.S. National Heart, Lung, and Blood Institute has more on stents.

SOURCES: John Gassler, M.D., associate professor of medicine, University of Rochester Medical Center, Rochester, N.Y.; Jean-Sebastien Hulot, M.D., Ph.D., associate professor of medicine and director, Pharmacogenomics & Personalized Therapeutics, Cardiovascular Research Center, Mount Sinai School of Medicine, New York City; Oct. 26, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Linking of mutations in 12 genes to ovarian cancer may lead to more effective prevention
2. Happy Kids a Product of Genes, Parenting, Study Finds
3. New Genes Revealed for Type 1 Diabetes
4. Scientists ID More Genes Linked to Heart Disease
5. Genes May Explain Blacks Bleaker Prostate Cancer Stats
6. Key regulatory genes often amplified in aggressive childhood tumor of the brainstem
7. Family Heart Disease Risk Linked to Genes, Not Lifestyle
8. Intelligence Largely Rooted in the Genes
9. Johns Hopkins scientists map genes for common form of brain cancer
10. Genes, Not Healthy Living, Get Most to Age 100
11. Researchers Find 3 Genes Linked to Esophagus Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genes Could Highlight Plavix Users at Clot Risk After Stent
(Date:9/25/2017)... , ... September 25, 2017 , ... Earlypicker is expanding ... a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping the nation. ... company that’s already well-known for the great offerings that allow Koreans everywhere to look ...
(Date:9/25/2017)... ... ... Majestic Unicorn”: a poignant book that describes what happened to the animals—specifically on ... Dayna Chantel, an artist and a writer. , Chantel shares, “Animals of all kinds, ... Male and female, no matter what species, they were chosen to be saved. The ...
(Date:9/25/2017)... ... ... Borers kill Ash trees in as little as 1-3 years. The signs of ... Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in Northeast ... of decline from Emerald Ash Borers, two Ash trees continue to thrive. , ...
(Date:9/24/2017)... ... September 23, 2017 , ... Throughout the United States and the world, clinicians ... physicians, nurses and other providers work to give the best care possible to patients ... But U.S. Senators today are threatening to tie our hands in carrying out that ...
(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... “Star of ... “Star of Bethlehem Study” is the creation of published author, Duane Engdahl, an investigator ... Published by Christian Faith Publishing, Duane Engdahl’s new book is a thought-provoking essay an ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
(Date:9/1/2017)... -- Bayer will present the latest research from across its growing ... 2017 Congress, September 8-12 in Madrid, Spain ... data on Bayer,s marketed portfolio and late-stage compounds as well ... "We value the opportunity to meet ... ESMO," said Carsten Brunn , Head of Pharmaceuticals, Americas ...
Breaking Medicine Technology: